Selected article for: "antiviral agent and viral replication"
Author: Huang, Qi; Zhong, Yingyuan; Li, Jingyan; Ye, Yilu; Wu, Wenjiao; Chen, Lizhu; Feng, Mingkai; Yang, Jie; Liu, Shuwen
Title: Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication
  • Cord-id: d213qdsy
  • Document date: 2020_6_11
    • ID: d213qdsy
    Snippet: In this study, we examined the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clinical trials, on influenza A viruses (IAVs) and its antiviral mechanism. The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC(50) value of 3.35 ± 0.39, 7.01 ± 1.84 and 5.99 ± 1.89 μM, respectively. Moreover, roscovitine suppressed th
    Document: In this study, we examined the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clinical trials, on influenza A viruses (IAVs) and its antiviral mechanism. The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC(50) value of 3.35 ± 0.39, 7.01 ± 1.84 and 5.99 ± 1.89 μM, respectively. Moreover, roscovitine suppressed the gene transcription and genome replication steps in the viral life cycle. Further mechanistic studies indicated that roscovitine reduced viral polymerase activity and bound specifically to the viral PB2cap protein by fluorescence polarization assay (FP) and surface plasmon resonance (SPR). Therefore, we believed roscovitine, as a PB2cap inhibitor, was a prospective antiviral agent to be developed as therapeutic treatment against influenza A virus infection.

    Search related documents:
    Co phrase search for related documents
    • acidic protein and luciferase reporter: 1, 2
    • activity study and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • activity study and addition time assay: 1, 2, 3, 4, 5
    • activity study and luciferase activity: 1, 2, 3, 4
    • activity study and luciferase plasmid: 1
    • activity study and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activity study and lung inflammation: 1, 2, 3
    • activity study and madin darby: 1, 2, 3
    • addition time and luciferase activity: 1, 2, 3
    • addition time and luciferase expression: 1
    • addition time and luciferase reporter: 1
    • addition time and madin darby: 1, 2
    • addition time and madison wi: 1
    • addition time assay and luciferase activity: 1
    • addition time assay and madison wi: 1
    • luciferase activity and madin darby: 1
    • luciferase activity and madison wi: 1, 2, 3, 4, 5
    • luciferase expression and madison wi: 1
    • luciferase plasmid and lung inflammation: 1